

## Review Form 1.6

Journal Name:	<a href="#">Asian Journal of Research in Infectious Diseases</a>
Manuscript Number:	Ms_AJRID_90671
Title of the Manuscript:	COVID 19OMICRON: THE ORIGIN, PRESENTATION, DIAGNOSIS, PREVENTION AND CONTROL
Type of the Article	

### General guideline for Peer Review process:

This journal's peer review policy states that **NO** manuscript should be rejected only on the basis of '**lack of Novelty**', provided the manuscript is scientifically robust and technically sound. To know the complete guideline for Peer Review process, reviewers are requested to visit this link:

(<https://www.journalajrid.com/index.php/AJRID/editorial-policy> )

### PART 1: Review Comments

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
<b>Compulsory</b> REVISION comments		
<b>Minor</b> REVISION comments	<p>Dear Editor, Confidential</p> <p>a) The principal point of this study to: 1) summarize the latest research progress of the structure, epidemiology and pathogenesis; 2) look at the mutation pattern which is an important feature in virology of the virus; 3) look at the existing variants especially Omicron Variant.</p> <p>b) I think that this study is suitable, after minor revision, to be published onto your prestigious journal.</p> <p>Comments to Authors Authors are kindly requested to emphasize the current concepts about these issues in the context of recent knowledge and the available literature. This articles should be quoted in the References list.</p> <p>References</p> <ol style="list-style-type: none"> <li>1. Obesity, COVID-19 and immunotherapy: the complex relationship!. <i>Immunotherapy</i>. 2020;12(15):1105-1109. doi:10.2217/imt-2020-0178.</li> <li>2. Metabolic Syndrome, Alzheimer's Disease, and Covid 19: A Possible Correlation. <i>Curr Alzheimer Res</i>. 2021;18(12):915-924. doi:10.2174/1567205018666211209095652.</li> <li>3. SARS-CoV-2 hyperimmune intravenous human immunoglobulins neutralizes Omicron subvariants BA.1, BA.2, BA.2.12.1, BA.3 and BA.4/BA.5 for treatment of COVID-19 [published online ahead of print, 2022 Aug 4]. <i>Clin Infect Dis</i>. 2022;ciac642. doi:10.1093/cid/ciac642.</li> <li>4. Zhan W, Tian X, Zhang X, et al. Structural Study of SARS-CoV-2 Antibodies Identifies a Broad-Spectrum Antibody That Neutralizes the Omicron Variant by Disassembling the Spike Trimer [published online ahead of print, 2022 Aug 4]. <i>J Virol</i>. 2022;e0048022. doi:10.1128/jvi.00480-22</li> </ol>	
<b>Optional/General</b> comments		

### PART 2:

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
Are there ethical issues in this manuscript?	(If yes, Kindly please write down the ethical issues here in details)	

[Review Form 1.6](#)

**Reviewer Details:**

Name:	<b>Carmine Finelli</b>
Department, University & Country	<b>Italy</b>